Literature DB >> 7709006

The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD.

A G Stewart1, J C Waterhouse, P Howard.   

Abstract

Patients with hypoxaemic chronic obstructive pulmonary disease (COPD) have a subclinical autonomic neuropathy. Autonomic neuropathy has been associated with a prolonged electrocardiograph QTc interval and risk of ventricular arrhythmias and death. We studied cardiovascular autonomic nerve function and QTc interval at rest and during stress (a valsalva manoeuvre) in 34 patients with hypoxaemic COPD who were followed up after 2 yr. Seventeen patients had a subclinical autonomic neuropathy (group AN) and the remaining 17 were normal (group C). Group AN were significantly more hypoxaemic (PaO2 7.3 +/- 0.3 compared to 9.2 +/- 1.8, P < 0.05), had a lower FEV1 and had a longer QTc at rest (0.43 +/- 0.01 compared to 0.40 +/- 0.01, P < 0.01) and at peak valsalva (0.44 +/- 0.01 compared to 0.41 +/- 0.01, P < 0.05). When analysed after 2 yr, there were two deaths in group C and seven deaths in group AN. The QTc was abnormal > 0.44s at rest and at peak valsalva stress in five of group AN, three of these five patients died. QTc was normal at rest but abnormal at peak valsalva stress in eight further patients. This included three further patients from group AN of whom two had died and five group C patients which included both the group C deaths. The presence of autonomic neuropathy and QTc prolongation (> 0.44s) at rest was significantly associated (P < 0.05). Likewise QTc prolongation at the peak of a valsalva stress was significantly associated with death at 2 yr follow-up (P < 0.01) with an odds ratio of 11.1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7709006     DOI: 10.1016/0954-6111(95)90188-4

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  23 in total

Review 1.  QT dispersion: time for a revival?

Authors:  Alessandro Celi
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

2.  Lower arrythmogenic risk of low dose albuterol plus ipratropium.

Authors:  H Yuksel; S Coskun; M Polat; A Onag
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 1.967

3.  Increased QT dispersion: a negative prognostic finding in chronic obstructive pulmonary disease.

Authors:  Roberto Zulli; Paolo Donati; Franco Nicosia; Massimiliano De Vecchi; Claudio Tantucci; Giuseppe Romanelli; Vittorio Grassi
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  Lung function, percent emphysema, and QT duration: The Multi-Ethnic Study of Atherosclerosis (MESA) lung study.

Authors:  Hilary F Armstrong; Gina S Lovasi; Elsayed Z Soliman; Susan R Heckbert; Bruce M Psaty; John H M Austin; Jerry A Krishnan; Eric A Hoffman; Craig Johnson; Matthew J Budoff; Karol E Watson; R Graham Barr
Journal:  Respir Med       Date:  2016-12-08       Impact factor: 3.415

Review 5.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Effect of exercise induced hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease.

Authors:  R P Smith; M K Johnson; J Ashley; S T Rudkin; R J White
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

7.  Deep breathing heart rate variability is associated with respiratory muscle weakness in patients with chronic obstructive pulmonary disease.

Authors:  Michel Silva Reis; Ross Arena; Ana Paula Deus; Rodrigo Polaquini Simões; Aparecida Maria Catai; Audrey Borghi-Silva
Journal:  Clinics (Sao Paulo)       Date:  2010-04       Impact factor: 2.365

8.  Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study.

Authors:  D M Mannino; A S Buist; T L Petty; P L Enright; S C Redd
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 9.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 10.  Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.

Authors:  Andrea Rossi; Sonia Khirani; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.